Search

Your search keyword '"Rodriguez, M. Alma"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Rodriguez, M. Alma" Remove constraint Author: "Rodriguez, M. Alma" Database Unpaywall Remove constraint Database: Unpaywall
50 results on '"Rodriguez, M. Alma"'

Search Results

1. NCCN Guidelines® Insights: Survivorship, Version 1.2023

2. NCCN Guidelines® Insights: Survivorship, Version 1.2022

5. Survivorship, Version 1.2021

8. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy

9. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET–CT-documented First Remission

10. NCCN Guidelines Insights: Survivorship, Version 2.2020

12. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

15. NCCN Guidelines Insights: Survivorship, Version 2.2019

16. Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma

17. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

18. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy

19. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

20. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

21. Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

22. Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions

23. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma

24. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

25. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma

26. NCCN Guidelines Insights: Survivorship, Version 1.2016

27. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease

28. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

29. Targeting Wnt pathway in mantle cell lymphoma-initiating cells

30. Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography

31. Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma

32. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas

34. Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014

35. Survivorship: Nutrition and Weight Management, Version 2.2014

36. Survivorship: Healthy Lifestyles, Version 2.2014

37. Survivorship: Immunizations and Prevention of Infections, Version 2.2014

41. Dose‐Related Safety and Immunogenicity of Baculovirus‐Expressed Trivalent Influenza Vaccine: A Double‐Blind, Controlled Trial in Adult Patients with Non‐Hodgkin B Cell Lymphoma

42. Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center

43. Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin’s Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project.

45. CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin’s Disease: Associations With Presenting Features and Clinical Outcome

46. Primary Cutaneous Non-Hodgkin’s Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy

47. Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients

48. Phase II Study of Paclitaxel in Combination with Mitoxantrone and Ifosfamide/Mesna for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma after Failure to Cytarabine/Cisplatin Combination

49. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial

50. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

Catalog

Books, media, physical & digital resources